AbCellera Biologics (ABCL) EBT: 2020-2023
Historic EBT for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -$48.6 million.
- AbCellera Biologics' EBT fell 54.72% to -$48.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$174.0 million, marking a year-over-year decrease of 172.79%. This contributed to the annual value of -$200.4 million for FY2024, which is 15.15% down from last year.
- Per AbCellera Biologics' latest filing, its EBT stood at -$48.6 million for Q4 2023, which was down 23.74% from -$39.3 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' EBT registered a high of $230.8 million during Q1 2022, and its lowest value of -$48.6 million during Q4 2023.
- For the 3-year period, AbCellera Biologics' EBT averaged around $23.7 million, with its median value being -$15.9 million (2021).
- Data for AbCellera Biologics' EBT shows a peak YoY increase of 7,815.58% (in 2021) and a maximum YoY decrease of 827.29% (in 2021) over the last 5 years.
- AbCellera Biologics' EBT (Quarterly) stood at $161.2 million in 2020, then slumped by 47.44% to $84.7 million in 2021, then tumbled by 137.08% to -$31.4 million in 2022, then slumped by 54.72% to -$48.6 million in 2023.
- Its last three reported values are -$48.6 million in Q4 2023, -$39.3 million for Q3 2023, and -$38.0 million during Q2 2023.